Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research. The research found that RhopressaTM suppressed the activity of profibrotic …
Preclinical Ophthalmic Contract Research